Trevena, Inc. (TRVN), a biopharmaceutical company, on Tuesday announced that it has met the minimum bid price requirement set by the Nasdaq Stock Market LLC. As a result, Trevena's stock will continue to be listed on the Nasdaq Capital Market.
The company said it plans to release data from the clinical proof-of-concept studies for TRV045. Additionally, the company anticipates clinical outcomes from a study involving approximately 200 patients.
In the regular trading session on Friday the stock closed at $1.15, up $0.07 or 6.48%. However, during the premarket trading, the stock is currently trading at $1.1410, down $0.01 or 0.78%.
For comments and feedback: editorial@rttnews.com